Plasma biomarkers can be used to detect tau pathology in Down syndrome

Plasma p-tau217 proved an accurate blood-based biomarker of both tau and amyloid-beta pathological brain alterations for those with Down syndrome and may be used alone or with age as a covariate, per a study published in JAMA Neurology.
“[Down syndrome (DS)] is associated with a variety of clinical manifestations resulting from additional copies of protein-encoding genes located on chromosome 21, including the gene for the [amyloid precursor protein (APP)],” Shorena Janelidze, PhD, of the Clinical Memory Research Unit, department of clinical sciences at Lund University in Sweden,

Plasma p-tau217 proved an accurate blood-based biomarker of both tau and amyloid-beta pathological brain alterations for those with Down syndrome and may be used alone or with age as a covariate, per a study published in JAMA Neurology.
“[Down syndrome (DS)] is associated with a variety of clinical manifestations resulting from additional copies of protein-encoding genes located on chromosome 21, including the gene for the [amyloid precursor protein (APP)],” Shorena Janelidze, PhD, of the Clinical Memory Research Unit, department of clinical sciences at Lund University in Sweden,